US2007190127A1PendingUtilityA1

Extended release of neuregulin for improved cardiac function

58
Assignee: ZHOU MINGDONGPriority: Dec 30, 2005Filed: Dec 29, 2006Published: Aug 16, 2007
Est. expiryDec 30, 2025(expired)· nominal 20-yr term from priority
Inventors:Mingdong Zhou
A61P 9/04A61P 43/00A61P 9/00A61P 27/16A61P 35/00A61P 25/00A61P 25/28A61P 3/10A61P 27/02A61P 25/18A61P 21/04A61P 21/00A61K 38/1883A61K 47/60A61K 9/127A61K 9/0019A61K 48/00
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin.

Claims

exact text as granted — not AI-modified
1 - 85 . (canceled)  
     
     
         86 . An extended release composition for preventing, treating or delaying a disease or disorder in a mammal comprising an osmotic pump and a therapeutically effective amount of neuregulin.  
     
     
         87 . An extended release composition for preventing, treating or delaying a disease or disorder in a mammal comprising poly(ethylene glycol) and a therapeutically effective amount of neuregulin.  
     
     
         88 . An extended release composition for preventing, treating or delaying a disease or disorder in a mammal comprising a liposome and a therapeutically effective amount of neuregulin.  
     
     
         89 . An extended release composition for preventing, treating or delaying a disease or disorder in a mammal comprising a microsphere and a therapeutically effective amount of neuregulin.  
     
     
         90 . A method for preventing, treating or delaying heart failure in a mammal, the method comprising extended release of neuregulin into a mammal.  
     
     
         91 . The method of  claim 90 , wherein the extended release of NRG into a mammal enhances the EF value of the mammal.  
     
     
         92 . The method of  claim 91  wherein the EF value of the mammal is enhanced by a percentage selected from the group consisting of greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50% and greater than about 60%.  
     
     
         93 . The method of  claim 90 , wherein the extended release of NRG into a mammal enhances the FS value of the mammal.  
     
     
         94 . The method of  claim 93  wherein the FS value of the mammal is enhanced by a percentage selected from the group consisting of greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50% and greater than about 60%.  
     
     
         95 . The method of  claim 90 , wherein the extended release of NRG into a mammal reduces the interior diameter of the left ventricle (LVEDD or LVESD).  
     
     
         96 . The method of  claim 95 , wherein the LVEDD value is reduced by a percentage selected from the group consisting of greater than about 2%, greater than about 5%, greater than about 10% and greater than about 15%.  
     
     
         97 . The method of  claim 95 , wherein the LVESD value is reduced by a percentage selected from the group consisting of greater than about 2%, greater than about 5%, greater than about 10%, greater than about 15% and greater than about 20%.  
     
     
         98 . The method of  claim 90 , wherein the extended release of neuregulin into a mammal induces sustained activation of the ERK signaling pathway in cardiac cells.  
     
     
         99 . The method of  claim 90 , wherein the extended release of neuregulin into a mammal induces sustained activation of the AKT signaling pathway in cardiac cells.  
     
     
         100 . The method of  claim 90 , herein the extended release of neuregulin into a mammal is accomplished by attaching a polymer to neuregulin.  
     
     
         101 . The method of  claim 100 , wherein said polymer is poly(ethylene glycol).  
     
     
         102 . The method of  claim 100 , wherein said polymer is a poly(ethylene glycol) derivative.  
     
     
         103 . The method of  claim 90 , wherein the extended release of neuregulin into a mammal is accomplished through the use of liposomes.  
     
     
         104 . The method of  claim 90 , wherein the extended release of neuregulin into a mammal is accomplished through the use of microspheres.  
     
     
         105 . The method of  claim 90 , wherein the neuregulin is selected from the group comprising NRG1, NRG2, NRG3 and NRG4.  
     
     
         106 . The method of  claim 90 , wherein the neuregulin comprising the epidermal growth factor-like (EGF-like) domain, wherein the EGF-like domain is encoded by neuregulin 1 gene.  
     
     
         107 . The method of  claim 90 , wherein the extended release of neuregulin comprising continuously injection or infusion of neuregulin for 1 min to 24 hours per day.  
     
     
         108 . The method of  claim 90 , wherein the extended release of neuregulin including continuously intravenously infusion or injection of neuregulin for 4 or more hours per day.  
     
     
         109 . The method of  claim 90 , wherein the extended release of neuregulin including continuously hypodermically infusion or injection of neuregulin for 6 or more hours per day.  
     
     
         110 . A method for reducing a side effect in a mammal subjected to neuregulin treatment, the method comprising extended release of neuregulin into a mammal.  
     
     
         111 . The method of  claim 110 , wherein the side effect is gastrointestinal disorder or pericardial effusion.

Join the waitlist — get patent alerts

Track US2007190127A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.